FEQ1 Stock Overview
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for FEQ1 from our risk checks.
Laboratorio Reig Jofre, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.46 |
| 52 Week High | €2.82 |
| 52 Week Low | €2.18 |
| Beta | 0.89 |
| 1 Month Change | -0.81% |
| 3 Month Change | 4.68% |
| 1 Year Change | 0.82% |
| 3 Year Change | -51.67% |
| 5 Year Change | n/a |
| Change since IPO | 9.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| FEQ1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.8% | 0.9% | -1.0% |
| 1Y | 0.8% | -27.7% | 2.0% |
Return vs Industry: FEQ1 exceeded the German Pharmaceuticals industry which returned -27.9% over the past year.
Return vs Market: FEQ1 underperformed the German Market which returned 2.5% over the past year.
Price Volatility
| FEQ1 volatility | |
|---|---|
| FEQ1 Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FEQ1 has not had significant price volatility in the past 3 months.
Volatility Over Time: FEQ1's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 1,331 | Ignasi Reig | www.reigjofre.com |
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers medical devices, cosmetics, parapharmacy, and animal food related products; and biotechnological and health products. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, joint health and pain, women’s health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Forté Pharma brand.
Laboratorio Reig Jofre, S.A. Fundamentals Summary
| FEQ1 fundamental statistics | |
|---|---|
| Market cap | €200.15m |
| Earnings (TTM) | €9.41m |
| Revenue (TTM) | €317.95m |
21.3x
P/E Ratio0.6x
P/S RatioIs FEQ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FEQ1 income statement (TTM) | |
|---|---|
| Revenue | €317.95m |
| Cost of Revenue | €141.06m |
| Gross Profit | €176.89m |
| Other Expenses | €167.48m |
| Earnings | €9.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 55.63% |
| Net Profit Margin | 2.96% |
| Debt/Equity Ratio | 19.0% |
How did FEQ1 perform over the long term?
See historical performance and comparison